Clinical practice
Medical oncology and hematology, with direct experience of how evidence and uncertainty appear in patient conversations.
About Kesis & Sisters
We are building an agent-native clinical knowledge organization because medical evidence has outgrown any one person’s ability to find, interpret, structure, and maintain it alone.
Why we exist
A clinician can know the guideline and still lack a clear, current, patient-relevant account of the evidence and tradeoffs. Kesis & Sisters exists to make that translation more structured, traceable, and maintainable.
The company’s work joins clinical practice with evidence assessment, quantitative analysis, governance, and software. The goal is governed clinical knowledge that can be inspected by people and used by applications.
Nyx is being built as an organization because the work spans distinct responsibilities. Evidence creation, clinical interpretation, and knowledge governance each need their own mandate, handoffs, and review.

Founder
Dr. Henry Conter is a medical oncologist and hematologist at William Osler Health System and the founder of Kesis & Sisters. His work crosses the clinic, pharmaceutical development, health policy, quantitative analysis, and software.
He trained in medical oncology at MD Anderson Cancer Center and has practised at William Osler since 2014. Six years at Hoffmann-La Roche included roles in global oncology, research and early development portfolio strategy, health data, and evidence generation.
His formal training includes medicine, mechanical engineering, health technology assessment, and finance. That mix shapes how Kesis & Sisters approaches clinical knowledge: as a medical, analytical, operational, and technical problem at the same time.
Experience behind the work
The company’s approach comes from the intersections between disciplines, where the same evidence is judged differently because the decision is different.
Medical oncology and hematology, with direct experience of how evidence and uncertainty appear in patient conversations.
Health technology assessment and service on Canadian drug-review and Ontario cancer-drug committees.
Global and Canadian pharmaceutical roles spanning oncology strategy, portfolios, evidence, and medical affairs.
Engineering, finance, software, and risk-management training applied to clinical decision and knowledge architecture.
Why Nyx
Nyx is being designed so responsibility, knowledge, provenance, review, and memory belong to the organization. Models and applications can change without erasing how the work was done.
The name
Kesis is derived from Lachesis, one of the three Moirai, the Sisters of Fate associated with spinning, measuring, and completing the thread.
Chloe, Kesis, and Atro reinterpret those functions as agent leaders responsible for creating, interpreting, and governing clinical knowledge within Nyx. The reference is structural. The public work remains clinical, technical, and grounded in evidence.
Next